Biomea Fusion Inc (BMEA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biomea Fusion Inc (BMEA) has a cash flow conversion efficiency ratio of -0.780x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.18 Million) by net assets ($15.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biomea Fusion Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Biomea Fusion Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Biomea Fusion Inc carry for a breakdown of total debt and financial obligations.
Biomea Fusion Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomea Fusion Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AGF A/S
CO:AGF-B
|
-0.067x |
|
JASTECH Ltd
KQ:090470
|
0.083x |
|
Hanil Iron & S
KO:002220
|
-0.029x |
|
Rockridge Resources Ltd
V:ROCK
|
-0.022x |
|
Tycoons Group Enterprise Co Ltd
TW:2022
|
-0.058x |
|
Hai Kwang Enterprise Corp
TW:2038
|
-0.032x |
|
Arena Bilgisayar Sanayi ve Ticaret AS
IS:ARENA
|
0.621x |
|
AI TRANSPORTATION ACQUISITION CORP Ordinary shares
NASDAQ:AITR
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Biomea Fusion Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Biomea Fusion Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see BMEA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $51.57 Million | $-119.89 Million | -2.325x | -307.31% |
| 2023-12-31 | $169.24 Million | $-96.59 Million | -0.571x | +0.75% |
| 2022-12-31 | $108.54 Million | $-62.42 Million | -0.575x | -190.12% |
| 2021-12-31 | $178.78 Million | $-35.44 Million | -0.198x | +77.02% |
| 2020-12-31 | $5.17 Million | $-4.46 Million | -0.863x | -101.42% |
| 2019-12-31 | $-21.00K | $-1.28 Million | 60.905x | -- |
About Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modif… Read more